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Unconventional infectious agents cause transmissible spongiform encephalopathy (TSE) 
diseases including scrapie and bovine spongiform encephalopathy (BSE) in animals and 
Creutzfeldt-Jakob disease in humans. The protein only hypothesis claims that the TSE agent 
is composed solely of the protein called prion (PrPsc)1. This protein is the misfolded form of a 
host-encoded cellular protein, PrPc exerting presumably a vital role at the synapse2. Even 
though now widely accepted, the prion concept fails to provide in certain circumstances3-6, a 
satisfying interpretation of the infectious phenomenon. Using the 263K scrapie-hamster 
model, we conducted a transmission study to search for a putative prion-associated factor 
indispensable for infectivity. Here we show that innocuous recombinant prion protein 
(recPrP) was capable, in a reproducible manner, of transmitting scrapie disease when the 
protein was β–sheet converted in a solution containing PrPsc-derived RNA material. Analysis 
of the PrP-RNA mixture revealed the association of recPrP with two prominent populations 
of small RNA molecules having an average length of about ~27 and ~55 nucleotides. We 
conclude that the nature of the TSE agent seems to be composed of a nucleoprotein molecular 
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complex, in which informative RNA molecules of small sizes are associated with the misfolded 
prion protein (PrPsc). 
 
More than a decade ago, experiments of BSE transmission in mice alerted the scientific community 
on the possibility that TSEs could be transmitted in the absence of detectable PrPsc 5. Subsequent 
studies studies have also shown the absence of a strict correlation between infectivity and PrPsc, 
suggesting that another component could be required for transmissibility of the TSE agent3,4,6. Here, 
we have reconsidered the fundamental question of the nature of TSE agent making use of recent 
technological developments in the prion field such as recombinant protein engineering and in vitro 
protein conversion. We set up the following strategy to search for a putative nucleic acid partner of 
PrPsc. After extensive destructive treatments, the native PrPsc pathological conformer eliminated 
from infectious preparations (called SAF for scrapie-associated fibrils which corrrespond to the 
amyloid filament form of the PrPsc), was replaced by an equivalent PrP molecule consisting of β-
sheeted recombinant PrP. As such, the recombinant protein constituted an appropriate tool to probe 
the conjectured nucleic acid previously released by the native PrPsc7. To demonstrate its presence, 
we reasoned that recPrP, during β-sheet conversion, could interact specifically with this nucleic 
acid to form a nucleoprotein complex that would transmit scrapie to recipient animals. 
Infectious SAF solution was prepared from 263K-infected hamster brain and exposed to a harsh 
protein destruction procedure involving phenol-chloroform and PK digestion. The resulting PrPsc-
free SAF-derived solution was either used as such or treated with DNAse I (as a control see 
Supplementary Methods) before it was mixed with various versions of recPrP. The different mixes 
were then inoculated to hamsters and their infectious potential investigated up to 545 days post-
inoculation (PI)(see Table 1). Unexpectedly, we achieved successful infection with the DNAse I-
treated sample (inoculum 8; see Table 1). Two sick animals out of five (40%) succumbed to disease 
with clinical symptoms of scrapie, at 151 and 246 days PI. None of the other animals from either 
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the PrPsc-free SAF-derived (inocula 2, 6, 7 and 11) or the controls (inocula 12 and 13) developed 
scrapie during an observation period of 545 days PI.  
We then characterized the nucleic acid content of our samples, using the Agilent 2100 Bioanalyzer. 
To have a more acurate view of the nucleic acids present before and after DNAse I digestion, we 
examined the parent solution of inoculum 8 (inoculum 2). This inoculum contains the crude nucleic 
acids extracted from PrPsc preparation. When subjected to DNAse I, we found that inoculum 2 
contained two distinct populations of small RNA of sizes averaging ~27 and ~55 nucleotides (Fig. 
1a). This solution showed a complete absence of contaminating or degraded large cellular RNA 
(Fig. 1b). By contrast, the DNAse I untreated original solution (inoculum 2) contained a large 
amount of cellular DNA (heterogenous mixture of sizes <300 nucleotides) masking the small RNA 
populations (Fig. 1c). We also investigated the molecular characteristics of inoculum 8. A fraction 
of the small RNA interacted with the recPrP as shown by its liberation from the protein after PK 
treatment (Supplementary Fig. 1a, c). Moreover, it was sensitive to RNAse A treatment 
(Supplementary Fig. 1a, b). Electron microscopy (EM) analysis of the recPrP in the inoculum 8 
(subjected to thermal β-sheet conversion) displayed occasional ovoidal and spherical aggregates 
(diameter ~7-40nm,; Fig. 1d). These supramolecular structures of recPrP were not observed in the 
control inoculum 7 containing alpha-recPrP (Fig. 1e), and no filament-like structures were observed 
in any of the solutions.  
To confirm these first results, we initiated a second experiment (ongoing > 360 days) with new 
solutions (see Table 1). The results up to now appear so convincing that they can be reasonably 
incorporated in this study.  Here, three animals out of nineteen (16%) died of scrapie disease (148, 
178 and 207 days PI) after injection with inoculum D which was prepared and treated with DNAse I 
in the same way as inoculum 8. Again, none of the negative control animals (29 : inocula A, B and 
C) are showing any clinical signs of scrapie (Table 1). Inoculum D also contained the two small 
RNA populations observed in the first experiment (Supplementary Fig. 1d).  
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To verify the animals infected with inoculum 8 died from an authentic scrapie disease, we 
performed neuropathological and PrP-immunohistochemistry analysis of their brains (Fig. 2 and 
Supplementary Fig. 2). Results of histopathology revealed spongiosis typical of TSE infection (Fig. 
2d,e and Supplementary Fig. 2b). The spongiosis lesion profile exhibited a much higher score than 
the 263K profile with particular emphasis on 11 and 9 brain regions (score difference (Sdf) ≥ 18) in 
animals 8.1 and 8.2 respectively (Fig. 3a). The brain of animal 8.1 and 8.2 also showed a more 
intense PrP staining (Fig. 3b). In the case of the second experiment, we analyzed one of the infected 
animals and found a neuropathology and a lesion profile distinct to the 263K strain (supplementary 
Fig. 3). Despite their lesion profile divergences, all infected animals showed a PrPsc western blot 
profile indistinguishable from the reference 263K scrapie strain (Supplementary Fig. 4a).  
In the present study, we were able to reveal RNA isolated from scrapie agent, as a factor essential 
for the acquisition of scrapie infectivity. Our strategy was based on the presumption that artificial 
recPrP, in its β-sheeted converted form, could become infectious upon binding to a natural putative 
RNA originating from PrPsc, thus demonstrating the existence of this genetic element and its 
contribution for infectivity. As expected, we observed that the PrPsc-free SAF preparation, obtained 
after protease and phenolic treatments was not infectious, but nevertheless still contained a 
component indispensable for infectivity released by the proteolysed PrPsc. This was demonstrated 
by injecting, into hamster brain, the DNAse I treated inoculum 8. Initially included as a control, this 
digestion became an essential supplementary step to completely eliminate the residual cellular DNA 
and allow the RNA material to associate with recPrP. Therefore, the lack of infectivity on the non 
DNAse I-treated sample (inoculum 6), can be explained by the inhibitory effect of the DNA (due to 
its large excess) that most likely hampered the formation of the ribonucleoprotein complex. Unlike 
the incomplete digestion of cellular DNA from the DNAse I treatment performed during the initial 
PrPscpurification step, the RNAse A pre-treatment appeared to eliminate all traces of cellular RNA. 
This suggested that the highly purified RNA recovered after PK digestion of PrPsc, was protected by 
this protein during the nuclease digestion. This RNA material of sizes averaging ~27 and ~55 
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nucleotides, was RNAse A sensitive indicating that it was constituted of single-strand molecules. 
Their interaction with recPrP (inoculum 8), was confirmed by their release after PK digestion. The 
β-sheeted recPrP in inoculum 8 adopted various supramolecular structures of ovoidal and spherical 
shapes (7-40 nm), not seen in the unconverted recPrP sample (inoculum 7), when observed by EM 
as previously shown9. Such small aggregates of PrPsc would be, according to recent data, the most 
infectious forms of prions10. In future experiments it will be interesting to further dicepher the 
molecular arrangement between β-sheeted PrP and its ribonucleic partner. A clear understanding of 
the role played by these intriguing RNA species in the infectious process will only be possible after 
identification of their sequences (work in progress). One crucial question is whether they are in any 
way related to recently discovered cellular ribo-regulators designated miRNA, siRNA and 
piRNA11,12. The possibility of such RNAs interacting with PrP has been evoked previously, but was 
immediately rejected because of the absence of data establishing a link between the RNA substrate 
and the infectious phenomenon 13,14. 
We have created in test tube a macromolecular complex consisting of hamster recPrP and RNA 
material extracted from 263K prions. The pathogenicity of this novel coupling was validated, after 
brain inoculation, by the development of neurological disease reflecting typical experimental 
scrapie in 5/24 (20%) wild-type animals taking into account the two experiments. However on first 
passage, a remarkable divergence between the infectious β recPrP-RNA complex created  in vitro 
and the natural 263K agent was observed in three tested animals. The lesions obtained with this new 
infectious entity were clearly more severe, characterized by intense spongiosis, important neuronal 
loss and gliosis. So the two most important points of our study, namely the absence of residual 
contamination of our samples and the infectious nature of the in vitro-generated biological entity 
were observed in both experiments. 
It is clear that the infectivity level of our preparations remains modest in that we chose to use 
minimal conditions essential to ensure the required effect. In future experiments it will be of great 
interest to explore variables able to improve the infectious nature of these preparations. It will also 
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be important to verify whether our biomacromolecular assemblage, able to generate an infraviral 
particle, satisfies the virino hypothesis, which dictates that the genome, protected by a coating 
cellular protein (PrP), is host-independent15-17. The two structural pieces composing the novel 
infectious entity, β-recPrP and PrPsc-associated RNAs, are by themselves not infectious. It is 
through their molecular synergy that infectivity manifests. However we cannot exclude the 
possibility that in exceptional circumstances, RNA alone might be able to initiate the infectious 
process4. Information encoded by the RNA sequences constitute a prerequisite for elucidating the 
replicative modalities of this new structural version of the scrapie agent. In keeping with the 
‘paradoxical’ prion, it is conceivable that the genetic moiety, as was discovered for PrP, might be 
host-encoded. Although it can be considered at the rough state, the present work provides serious 
clues to ultimately resolve in a near future the enigmatic nature of the TSE infectious agent 18.  
 
Methods summary 
 
Animals  and SAF preparation. 
Brains of hamsters infected with the 263K scrapie strain were collected at the terminal stage of the 
disease (~80 days; titer of 2x109, 50% lethal dose/ml) and pooled together to be used for SAF 
purification. PrPsc was  purified using the BioRad TeSeE purification kit according to the 
manufacturer’s instructions with one exception. Cellular DNA and RNA in the homogenate were 
digested prior to the PK step of the protocole. The BioRad purification was used to purify PrPsc to 
avoid too much compaction and facilitate subsequent digestion by PK.  
PrPscdestructive procedures. 
Two lines of attack were adopted to simultaneously suppress infectivity of SAF preparations, by 
destroying PrPsc and releasing the hypothetical PrPsc-associated nucleic acids. One, using phenol-
chloroform, and the other involving a high concentration of guanidinium-HCl which profoundly 
denatures PrPsc. In both cases, extensive proteinase K digestion completed the PrPsc destruction 
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protocole (see Supplementary) . The GdnHCl method was not successful and the data is not shown 
in this paper.  
Preparation of inocula 
The two types of treated SAF solutions constituted the reactive medium in which the conversion 
process of hamster recombinant alpha-PrP (AllPrion) took place. This was carried out using thermal 
conditions as previously described9 and two other in vitro conversion methods were also tested (see 
Supplementary Methods).  
Histopathology 
Formalin-fixed brains were embedded in paraffin and processed for histopathology and PrP 
immunocytochemistry as previously described19. The anti-PrP antibody used was SAF 32. Sections 
were analysed in double-blind fashion.  
Nucleic acid analysis 
One microliter of the solution was deposited in wells of a Lab-on-a-Chip device (2100 Bioanalyser, 
Small RNA Assay, and RNA 6000 Nano, Agilent Technologies) according to the manufacturer’s 
recommendations. 
Electron microcopy 
Five microliters of the  solution were deposited on grids and negatively stained as previously 
described9  
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Tables 
 
Table 1. Results of bioassays of phenol/chloroform group – First and second experiments   
 
 
 Inoculaa   Description Scrapie after IC
Death from 
other causes 
Residual 
infectivity
WB 
PrPsc
Incubation 
periodsb 
1 BioRad purified SAF 4/4 0/4 N/A + 85,85,85,85 
Experiment 1:  SAF treated with PK and Phenol/Chloroform (duration : 545 days) 
2 Treated SAF solution (SaS) 0/5 1/5
φ Noφ + 413φ 
6 SaS+ β-recPrP (72°C) 0/7 2/7 No - 300*, 424* 
7 SaS + α-recPrP 0/5 1/5 No - 310* 
8 SaS+ Dnase I +  β-recPrP (72°C) 2/5 1/5 No + 151, 246, 452* 
11 SaS + β-recPrP (urea) 0/7 3/7 No - 
424*, 508*, 
515* 
12 α - recPrP in MOPS 0/4c 0/4 No  545 c 
13 β- recPrP (72°C) in MOPS 0/2 1/2 No  410* 
Experiment  2:  SAF treated with PK and Phenol/Chloroform (ongoing > 280 days)
A Treated SAF solution 2 (SaS2) 0/7 0/7 No   
B SaS2+DNAse I 0/17 1/17 No - 279* 
C SaS2+DNAse I + α- recPrP 0/5 0/5 No   
D 
SaS2 + DNAse I + 
β-recPrP (72°C) 3/19 0/19 No + 148, 178, 207 
 
 
a, The order of inoculation was done randomly, excluding cross contamination; for example, the 
positive inoculum 8 followed the two negative inocula 6 and 7. b, Delay between injection and 
death/sacrifice at the time when the animal show severe clinical signs (ataxia, rachitism,tremor). c, 
All surviving animals were sacrified at 545 days post inoculation φ, Aberrant scrapie infection 
observed in one control animal that can be clearly attributed to enviromental contamination.  The 
animal (death at 413 days) lived in a cage with three animals of another experimental group injected 
with contaminated inoculum from an unsuccessful PrPsc removal protocole involving GnHCl (data 
not shown). These animals died at 231, 247 and 372 days and it is known that feces and urine are 
very efficient sources of infectivity20,21. This was confirmed by WB (Supplementary Fig. 4b, lane 3) 
and histopathology giving a lesion profile identical to 263K (Supplementary Fig. 5). *, These 
animals died of causes other than scrapie disease showed no clinical signs and no PrPsc 
accumulation (some are shown in Supplementary Fig. 4b).   
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Figures 
 
Figure 1: Nucleic acid analysis and recPrP nanostructural formation. a, Electropherogram of 
DNAse I digested inoculum 2 analysed with a small RNA assay chip, showing two distinct 
populations of RNA having an average length of about 27 and 55 nucleotides. b, Electropherogram 
of DNAse I digested inoculum 2 analysed with a large RNA integrity assay chip showing the 
absence of large cellular RNA contamination and degradation products. c, Inoculum 2 sample 
analysed with a small RNA assay chip,  showing the presence of contaminating cellular DNA (sizes 
≤ 300 nucleotides). d, Electron microphotography of inoculum 8 after negative staining showing the 
presence of ovoidal and spherical aggregated forms of PrP with a diameter range of 7 - 40 nm. e, 
Microphotography of control inoculum 7 showing the absence of PrP aggregates (scale bar100 nm). 
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Figure 2: Histopathology and PrP-Immunochemistry of infectious inoculum 8. Hematoxylin 
and eosin (H&E)-stained (two left columns) and PrP immunohistochemistry with SAF32 antibody 
(right column).  Control hamster (a, b, c), inoculum 8.1- infected hamster  (d, e, f) and SAF-
infected hamster (g, h, i). The inoculum 8.1-infected hamster brain showed an intense destruction of 
the hippocampus, cumulating extensive spongiosis, severe gliosis and neuronal loss (d, e). 
PrPscimmuno-detection displayed a diffuse and strong distribution (f) never seen in the SAF 
hamster group. 
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Figure 3: Spongiosis and PrP lesion profiles of infectious inoculum 8. a, Spongiosis profiles of 
hamsters inoculated with SAF (n=4; black). Two hamsters inoculated with inoculum 8 (8.1 blue, 
8.2 red). Spongiosis was scored on a scale of 0-3. The score of 0: no vacuoles, 3; highest degree of 
spongiosis observed. Eleven areas (1, 2, 3, 4, 5, 7, 9, 11, 13, 14, 16) showed a score difference ≥18 
between the SAF and 8.1 animals and nine (1, 2, 3, 4, 5, 8, 9, 10, 16) between the SAF and 8.2 
animals. b, PrP lesion profile (SAF32 antibody) scored on a scale of 0 to 4 with 0: no 
PrPscdeposition, 1: focal slight deposition, 2: diffuse slight, 3: focal strong, 4: diffuse strong 
deposition. Brain areas examined were: 1, pyriform cortex; 2, motor cortex; 3, septal nuclei; 4, 
striatum; 5, thalamus; 6, hypothalamus; 7, dentate gyrus; 8, CA1-2; 9, CA3-4; 10, superior 
colliculus; 11, pons/mesencephalon; 12, cerebellum; 13, dentate nucleus; 14, olivary nuclei; 15 
subcortical white matter; 16, cerebellum white matter.  
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 Supplementary Figure 1. Nucleic acid analysis of infectious inocula – 1st and 2nd 
experiments. a,  Infectious inoculum 8 showing the presence of the two RNA populations 
free in solution. b, Inoculum 8 treated with RNAse A. The total amount of free RNA is 
reduced when compared with a (see values in e). c, Inoculum 8 treated with PK to eliminate 
recPrP. The total amount of free RNA is increased when compared with a indicating its 
liberation from recPrP (see values in e). d, Infectious inoculum D showing the same two small 
RNA populations than in inoculum 8. Several measures performed independantly gave the 
following averages: a: 750 pg/μl (n=3) b: 320 pg/μl (n=2) and c: 1100 pg/μl (n=2). 
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Supplementary Figure 2. Histopathology of Septum – 1st experiment. Hematoxylin and 
eosin (H&E)-stained (top) and proteinase K-resistant prion protein (PrPsc) (bottom) from a 
healthy hamster (a, d), an inoculum 8-infected hamster (8.1) (b, e) and a SAF-infected 
hamster (c, f). The inoculum 8.1 infected hamster showed extensive spongiosis, severe gliosis 
and neuronal loss (b) and a focal and strong PrPscdistribution (e) in the Septum, never seen in 
the SAF hamster group. 
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 Supplementary Figure 3. Histopathology and lesion profiles – 2nd experiment. 
Hematoxylin and eosin (H&E)-stained from one animal of the inoculum D group that 
developped scrapie. a and b, Hippocampus showing lesions distinct to the 263K strain. c, 
Thalamus presenting extensive lesions similar to those observed in the first experiment. d, 
Hippocampus PrPsc deposition (with SAF32 antibody) showing a diffuse and strong 
distribution.  e, Spongiosis profiles of hamsters inoculated with i) SAF (n=4; circles) and ii) 
inoculum D (diamonds). See Figure 3 legend for score scale and brain areas description. 
Score
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Supplementary Figure 4. PrPsc detection in hamsters – 1st experiment. a, PrPscfrom brains 
of animals inoculated with inoculum 8 (lanes 3; 151 days, lane 4; 246 days). Lane 1: 263K 
positive control and lane 2: healthy control. b, PrPscfrom brains of animals inoculated with 
inocula 2* (lane 3; environmentally contaminated animal), 6 (lane 4), 7(lane 5), 11 (lane 6) 
and 15 (lane 7). Lane 1: 263K positive control and lane 2: healthy control. A selection of 
animals which died of a cause other than scrapie has been represented.   
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Supplementary Figure 5. Lesion profile of environmentally contaminated animal – 1st 
experiment. Spongiosis lesions profile of the environmentally contaminated animal 
(inoculum 2; squares) that died at 413 days compared with the SAF group (n=4; circles) 
showing a profile matching the 263K strain. 
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PrPsc purification from 263K-infected brains. Brain homogenate (20%) was prepared from 
263K-infected hamster brains collected at terminal stage of the disease (~80 days). The 
homogenate was incubated with 20μg/ml of RNAse A (Ambion) at 37°C for 2hrs. Then, 
CaCl2 was added to a final concentration of 5mM and the homogenate was incubated for an 
additional 2hrs with 20U/ml of DNAse I (Roche). PrPsc was then purified from this 
homogenate using the BioRad TeSeE purification kit according to the manufacturer’s 
instructions (500 μl of homogenate per Bio-Rad reaction tube).  
Phenol/Chloroform PrPsc elimination method. Bio-Rad pellets (see PrPsc purification) were 
resuspended into 50 μl of PBS containing 0.5 % SDS and sonicated for 1 minute at highest 
setting. The pellet solutions from 10 tubes (total : 500 μl) were pooled together and kept at 
4°C. The following day, the solution was mixed with 2500 μl of PBS – 0.5% SDS containing 
500μg/ml of PK and incubated overnight at 37°C (~24 hrs). The next day, the PK reaction 
was stopped by heating the sample at 70°C for 5 minutes. Nucleic Acids were then purified 
from this solution by mixing with Phenol – chloroform – isoamyl alcohol (25:24:1) (# 77617 
Sigma) and extracting the aqueous phase. Extreme caution was taken to avoid touching the 
meniscus containing the denatured proteins and potentialy residual PrPsc. This protocole 
results in a solution devoid of PrPsc. 1 μl /ml of SUPERase-In (Ambion) solution was then 
added to protect from the action of unwanted RNAses. From this stage on, all reagents and 
material were prepared RNAse-free. This ‘A solution’ was then mixed with various 
recombinant PrP preparations (see below).   
Normalization of samples. Based on previous experience in the laboratory with the 263K 
model, we estimated the PrPsc quantity in the Bio-Rad pellets (see PrPsc purification) to be 
between 5 and 10 μg. We designated this initial estimated quantity as the ‘equivalent PrPsc’.  
The initial quantity was not so important however, but was simply used as a measure for 
normalizing the different samples throughout the experiment and also as an indicator of how 
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much recombinant PrP needed to be added to the different samples. All samples were 
normalized throughout the experiments using the ‘equivalent PrPsc’ values. 
Recombinant hamster PrP. The recombinant PrP used for these experiment was hamster 
PrP (23-231) from Allprion (P00025). The powder was resuspended in Milli-Q H2O at a 
concentration of 1 μg/μl. Once diluted in water, the protein is stable for at least two years at  
-20 °C.  
β-sheeted oligomeric recPrP preparations. The ‘A’ solution was dialysed against 20 mM 
MOPS Na+ pH 7.2 (MOPS buffer) using Slide-A-Lyzer 2K MWCO dialysis cassettes (Pierce) 
according to manufacturer’s instructions. The buffer was replaced with fresh buffer after 3 
hours and the dialysis was left to continue overnight. The next day, the ‘equivalent PrPsc’ of 
the solution was calculated (taking into account the initial volume and final volume after 
dialysis) and used with the following preparations:  
 For 72°C β-sheeted recPrP (‘A’: Inoculum 6), 4 μg of ‘equivalent PrPsc’ from MOPS 
dialysed solution ‘A’ was combined with MOPS buffer to a final volume of 400 μl. In 
parallel, 4 μl (1 μg/μl) of recombinant hamster PrP (recPrP; allprion) was added to 96 μl of 20 
mM MOPS Na+ pH 7.2 and heated at 72°C for 20 minutes and mixed immediately with the 
400 μl prepared. In these conditions, the recPrP forms β-sheeted PrP oligomers 9. 
 For 72°C β-sheeted recPrP + DNAse I (‘A’ : Inoculum 8), 4 μg of ‘equivalent PrPsc’ from 
MOPS dialysed solution ‘A’ was combined with MOPS buffer to a final volume of 400 μl and 
1μl of 2M CaCl2 (final concentration 4mM) and 1 μl of DNAse I was added. The solution 
was then heated at 37°C for 60 minutes and subsequently 75°C for 10 minutes to inactivate 
the DNAse. In parallel, 4 μl (1 μg/μl) of recPrP was added to 96  μl of 20 mM MOPS Na+ pH 
7.2 and heated at 72°C for 20 minutes and mixed immediately with the 400 μl prepared 
initially. 
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 β-sheeted recPrP fibrils preparations. The ‘A’ solution was dialysed against 0.2 M 
NaCl, 50mM sodium acetate pH 5 (sodium acetate buffer) using Slide-A-Lyzer 2K MWCO 
dialysis cassettes (Pierce). The buffer was replaced with fresh buffer after 3 hours and the 
dialysis was left to continue overnight. The next day, the ‘equivalent PrPsc’ of the solution 
was calculated and used with the following preparations:  
 For 'A’: Inoculum 11, 4 μl (4 μg) of hamster recPrP and 1 μl of SUPERase-In was added 
to 140 μl of sodium acetate buffer containing 10M urea. In parallel, 4 μg of ‘equivalent PrPsc’ 
of the sodium acetate dialysed solution ‘A’ was brought to a final volume of 350 μl in sodium 
acetate buffer and then mixed with the 145 μl. The final solutions were incubated at 37°C for 
~48hrs.  In these conditions, the recPrP should form PrP fibrils22. The resulting mix was 
dialysed against PBS using Slide-A-Lyzer 2K MWCO dialysis cassettes. The PBS was 
replaced after 3 hours and the dialysis left to continue overnight. The next day, the ‘equivalent 
PrPsc’ was calculated and the solution diluted and injected in hamsters (see injection protocole 
below)  
Controls. Several controls were injected in hamsters. The details of the preparation of these is 
described here. 
 For inoculum 1 (Bio-Rad purified SAFs), 20ul of the pellet solution (100 ng/μl of 
‘equivalent PrPsc’) was diluted in 480 μl of MOPS buffer.  
 For inoculum 2, 2 μg of ‘equivalent PrPsc’ from solution ‘A’ was diluted to a final volume 
of  500 μl of MOPS buffer.  
 For inoculum 12 (alpha recPrP alone) 2 μg of hamster recPrP was diluted directly in a final 
volume of 500 μl of MOPS buffer the day of the injection.  
  For inoculum 13 (β- recPrP (72°C) in MOPS), 4 μg (1 μg/μl) of recPrP was added to 96  μl 
of 20 mM MOPS Na+ pH 7.2 and heated at 72°C for 20 minutes and mixed immediately with 
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400 μl of MOPS buffer. This sample was then diluted to the proper dilution the day of the 
injection (see injection protocole below). 
 For inoculum 7, 4 μg of ‘equivalent PrPsc’ from solution ‘A’ was combined with MOPS 
buffer to a final volume of 400 μl and then mixed with 100 μl of alpha recPrP solution (4 μg). 
 Injection into golden syrian hamsters. All samples were kept at 4°C until injection day 
(no longer than 3 days) and prepared for injection (diluted) on the day of the injection. 
Samples were diluted to a final ‘equivalent PrPsc’ of 4 ng/μl with either PBS or MOPS buffer 
depending on the buffer of the solution injected. Each hamster received a total of 50μl in the 
right hemisphere of the brain. Gloves were changed in between each inoculum to avoid 
contaminations. The order of injection was: inocula 1, 2, 7, 8, 6, 11, 12, 13.  
  For the second experiment, the injections were performed in the same way as 
in the first experiment. 
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